ARS Pharmaceuticals Inc SPRY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
-
SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
-
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY
-
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
-
ARS Pharmaceuticals Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
-
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY
-
SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
-
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY
Trading Information
- Previous Close Price
- $4.07
- Day Range
- $3.81–4.08
- 52-Week Range
- $3.81–13.15
- Bid/Ask
- $3.80 / $4.02
- Shares Outstanding
- 99.45M
- Market Cap
- $399.78M
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.41
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 200
- Website
- https://www.ars-pharma.com
Valuation
|
Metric
|
SPRY
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 31.95 |
Price/Sales | 3.41 |
Price/Cash Flow | — |
Price/Earnings
SPRY
Financial Strength
|
Metric
|
SPRY
|
|---|---|
Quick Ratio | 3.13 |
Current Ratio | 3.48 |
Interest Coverage | — |
Quick Ratio
SPRY
Profitability
|
Metric
|
SPRY
|
|---|---|
Return on Assets (Normalized) | −59.38% |
Return on Equity (Normalized) | −174.40% |
Return on Invested Capital (Normalized) | −100.42% |
Return on Assets
SPRY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|ZP$&mMq | LOCK|&nsB | $127B | |||
| Moderna Inc
MRNA
| LOCK|^LmPx^ | LOCK|XF< | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|ZY!hM> | LOCK|W#Qrf | $81B | |||
| argenx SE ADR
ARGX
| LOCK|ztPsrG< | LOCK|gt | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%@@QC@p | LOCK|Wms | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$V$N@%q | LOCK|!F#bs | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|yg!XG%D | LOCK|#!tK& | $27B | |||
| Incyte Corp
INCY
| LOCK|%$c$<B# | LOCK|ljn | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|W?!dK>v | LOCK|p% | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Q#SlfY | LOCK|Mr | $14B |
United States